SCHEMBL453916

SCHEMBL453916

N[C@@H](CC(=O)O)C(=O)NCCO

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
DPP7 Q9UHL4 2/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
RRM1 P23921 1/20 0.36
ECE1 P42892 1/20 0.36
LTA4H P09960 2/20 0.35
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
S1PR1 P21453 1/20 0.33
S1PR3 Q99500 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3441238 1.00 MEN1 (0.50) MEN1USP2ALDH1A1MAPTKMT2A
Aspartic Acid SCHEMBL8594964 0.94 MEN1 (0.45) MEN1USP2ALDH1A1MAPTKMT2A
SCHEMBL1374079 0.88 DPP7 (0.44) MEN1USP2ALDH1A1MAPTKMT2A
SCHEMBL3229876 0.85 RRM1 (0.46) ALDH1A1DPP7RRM1GNAI3GNAO1
SCHEMBL8230008 0.83 MEN1 (0.50) MEN1USP2ALDH1A1MAPTKMT2A
SCHEMBL453917 0.83 MEN1 (0.50) MEN1USP2ALDH1A1MAPTKMT2A
SCHEMBL2806338 0.83 ECE1 (0.51) DPP7ECE1
SCHEMBL4759296 0.83 DPP7 (0.44) DPP7RRM1ECE1LTA4HGNAI3
SCHEMBL3261069 0.82 DPP7 (0.50) USP2DPP7TSHRRRM1ECE1
SCHEMBL9374114 0.82 DPP7 (0.38) DPP7RRM1ECE1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4545964-A2 CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS Juno Therapeutics GmbH (DE) 2025-04-30 EP claimed
WO-2025083196-A1 A METHOD OF MANUFACTURING A CELLULAR THERAPY PRODUCT AND RESPECTIVE KITS AND DEVICES TQ THERAPEUTICS GMBH (DE) 2025-04-24 WO claimed
US-20250020556-A1 CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS JUNO THERAPEUTICS GMBH (DE) 2025-01-16 US claimed
EP-2817625-B1 CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS JUNO THERAPEUTICS GMBH (DE) 2025-01-01 EP claimed
US-20240238176-A1 ANTI-POLLUTION ECO-FRIENDLY MATERIAL AND METHOD FOR PREPARING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2024-07-18 US claimed
EP-3483611-B1 INTACT MASS DETERMINATION OF PROTEIN CONJUGATED AGENT COMPOUNDS SEAGEN INC (US) 2023-01-04 EP claimed
US-20220056083-A1 STREPTAVIDIN MUTEINS AND METHODS OF USING THEM IBA LIFESCIENCES GMBH (GI) 2022-02-24 US claimed
US-11169158-B2 Intact mass determination of protein conjugated agent compounds SEAGEN INC. (US) 2021-11-09 US claimed
US-20210252169-A1 Multi-Functional Infrared-Emitting Composites RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2021-08-19 US claimed
US-10814017-B2 Multifunctional infrared-emitting composites RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-10-27 US claimed
US-20130028951-A1 Polymer-Liposome Nanocomposite Composition for Percutaneous Absorption, and Method for Preparing Same AMOREPACIFIC CORPORATION (KR) 2013-01-31 US claimed
EP-2545100-A2 A BIODEGRADABLE POLYMERIC HYDROGEL COMPOSITION Council of Scientific & Industrial Research (IN) 2013-01-16 EP claimed
WO-2011111067-A2 A BIODEGRADABLE POLYMERIC HYDROGEL COMPOSITION COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2011-09-15 WO claimed
EP-0749452-B1 POLYMER-CONJUGATED MALONIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS AND DIAGNOSTIC AGENTS GLYCOREX AB (SE) 2002-07-17 EP claimed
EP-0535387-B2 Echographique particle, preparation and application HOECHST AG (DE) 2001-10-04 EP claimed
US-5817742-A Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents HOECHST AKTIENGESELLSCHAFT (DE) 1998-10-06 US claimed
US-5811538-A NORMAL PHASE COLUMN CHROMATOGRAPHY ON SUPPORT COMPRISING POLYHYDROXYETHYL ASPARTAMIDE, SILICA, HYDROPHILIC SILICA GENTA, INCORPORATED (US) 1998-09-22 US claimed
US-5776875-A Use of biodegradable polymers in preventing scale build-up NALCO CHEMICAL COMPANY (US) 1998-07-07 US claimed
EP-0535387-B1 Echographique particle, preparation and application HOECHST AG (DE) 1996-08-21 EP claimed
WO-1995018137-A1 IMPROVED PROCESS FOR THE PURIFICATION OF OLIGOMERS GENTA INCORPORATED (US) 1995-07-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130028951-A1 Polymer-Liposome Nanocomposite Composition for Percutaneous Absorption, and Method for Preparing Same LIPA, LPXN, SLC7A1 MEN1 510/4885USP2 860/4885ALDH1A1 4748/4885
US-20240238176-A1 ANTI-POLLUTION ECO-FRIENDLY MATERIAL AND METHOD FOR PREPARING THE SAME CUTA, EXOSC9, EXOSC10 MEN1 2783/4885USP2 1837/4885ALDH1A1 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.